Claims
- 1. A method for treating a mammal in need of immunosuppression, comprising administering to the mammal an effective amount of a spiperone derivative of the formula: ##STR7## wherein R.sub.1 =H, CH.sub.3 --, C.sub.6 H.sub.5 --, cyclohexyl, 4-(OCH.sub.3)C.sub.6 H.sub.4 --, 3-(CH.sub.3)C.sub.6 H.sub.4 --, 4-(CH.sub.3)C.sub.6 H.sub.4 --, 4-X--C.sub.6 H.sub.4 --, (CH.sub.3).sub.2 CH--, CH.sub.3 (CH.sub.2).sub.3 --, (CH.sub.3).sub.2 CHCH.sub.2 --, CH.sub.3 CH.sub.2 CH(CH.sub.3)--, (CH.sub.3).sub.3 C--; or Y--CH.sub.2 (CH.sub.2).sub.m --.
- R.sub.2 H or CH.sub.3 ;
- R.sub.3 =H, CH.sub.3, CH.sub.3 CH.sub.2 --, CH.sub.3 CH.sub.2 CH.sub.2 --, (CH.sub.3).sub.2 CH--, CN(CH.sub.2).sub.2 --, or CH.sub.3 (CH.sub.2).sub.s --;
- R.sub.4 =H, C.sub.6 H.sub.5 CH(CH.sub.2 CH.sub.3)CH.sub.2 --, C.sub.6 H.sub.5 CH(CH.sub.3)(CH.sub.2).sub.2 --, C.sub.6 H.sub.5 CH.sub.2 CH(CH.sub.3)CH.sub.2 --, C.sub.6 H.sub.5 CH.sub.2 CH.sub.2 CH(CH.sub.3)--, C.sub.6 H.sub.5 CH(CH.sub.3)(CH.sub.2).sub.3 --, 4-CH.sub.3 C.sub.6 H.sub.4 CH(CH.sub.3)(CH.sub.2).sub.3 --, 4-(CH.sub.3 O)C.sub.6 H.sub.4 CH(CH.sub.3)(CH.sub.2).sub.3, 4-X--C.sub.6 H.sub.4 CH(CH.sub.3)CH.sub.2 --, 4-X--C.sub.6 H.sub.4 CH(CH.sub.2 CH.sub.3)CH.sub.2 --, 4-X--C.sub.6 H.sub.4 CH(CH.sub.3)(CH.sub.2).sub.2 --, 4-X--C.sub.6 H.sub.4 --CH(CH.sub.3)(CH.sub.2).sub.3 --, C.sub.6 H.sub.5 CH(OCH.sub.3)(CH.sub.2).sub.2 --, ##STR8## C.sub.6 H.sub.5 CO(CH.sub.2).sub.3 --, C.sub.6 H.sub.5 CO(CH.sub.2).sub.4 --, 4-(CH.sub.3)C.sub.6 H.sub.4 CO(CH.sub.2).sub.3 --, 4-(CH.sub.3 O)C.sub.6 H.sub.4 CO(CH.sub.2).sub.3 --, 4-X--C.sub.6 H.sub.4 CO(CH.sub.2).sub.3 --, 4-X--C.sub.6 H.sub.4 CO(CH.sub.2).sub.3 --, 2-thienyl--CO(CH.sub.2).sub.3 --, ##STR9## 4-XC.sub.6 H.sub.4 C(CH.sub.3)CH(CH.sub.2).sup.-.sub.2, where the conformation about the double bond is cis or trans,
- 4-XC.sub.6 H.sub.4 C(CH.sub.3)CHCH.sub.2.sup.-, where the conformation about the double bond is cis or trans,
- 4-X--C.sub.6 H.sub.4 COCH.dbd.CHCH.sub.2, or
- --Y--CH.sub.2 (CH.sub.2).sub.s.
- wherein n=3 or 4; m is between 1 to 4; s is between 1 to 6; X=is a heteroatom or a substituted heteroatom such as F, Cl, Br, I, OCH.sub.3, SO.sub.3.sup.-, or NH.sub.2 ; Y=H or a heteroatom such as F, Cl, Br, I, SO.sub.3, PO.sub.4.sup.=, OH, SH, SCH.sub.3, CH.sub.3 SO.sub.2.sup.-, NH.sub.2, --CO.sub.2.sup.- ; and each of Ar and Ar.sub.1 is, independently, H, C.sub.6 H.sub.5 --, 4-(CH.sub.3)C.sub.6 H.sub.4 --, 4-(CH.sub.3 O)C.sub.6 H.sub.4 --, 4-X--C.sub.6 H.sub.4 --, 3-(CX.sub.3)C.sub.6 H.sub.4 --, 2-thienyl, or 4-X--C.sub.6 H.sub.4 CH.sub.2 --
- in a carrier selected from the group suitable for systemic pharmaceutical administration to immunosuppress the mammal.
- 2. The method of claim 1, wherein the spiperone derivative has a binding affinity for a dopamine receptor of one tenth or less, and which is at least 50% as active on a weight basis in suppressing an immunological response, as that of the compound of the structure: ##STR10##
- 3. The method of claim 1 wherein the mammal is human.
- 4. The method of claim 1, wherein the spiperone derivative has a binding affinity for a serotonin receptor of one tenth or less, and which is at least 50% as active on a weight basis in suppressing an immunological response, as that of the compound of the structure: ##STR11##
- 5. The method of claim 1, wherein the dosage is between 0.1 mg/kg to 500 mg/kg of body weight per day as a single daily dose or divided daily doses.
- 6. The method of claim 1 wherein the spiperone derivative is administered in a time release formulation.
- 7. The method of claim 1, further comprising providing the spiperone derivative as a cycloamylose complex.
- 8. The method of claim 1, wherein the spiperone derivative is administered in combination with a compound selected from the group consisting of antivirals, antifungals, antibiotics, antiinflammatories, and other immunosuppressants.
Parent Case Info
This application is a continuation in part of Ser. No. 494,740 filed Mar. 3, 1990, now abandoned.
US Referenced Citations (8)
Non-Patent Literature Citations (2)
Entry |
Moerlein et al, "Effect of Lipophilicity on the In Vivo Localization of Radiolabelled Spiperone Analogues", Int. J. Nucl. Med. Biol. 12, 353-56 (1985). |
Nakanishi et al, "Spirohydantoin Derivatives", Chemical Abstracts, 75, 437 (1971), Abstract 110315n. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
494740 |
Mar 1990 |
|